Androgens
4
0
1
2
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 27/100
0.0%
0 terminated out of 4 trials
100.0%
+13.5% vs benchmark
25%
1 trials in Phase 3/4
50%
1 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (4)
A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)
Comparison Between Calculated Bioavailable Testosterone Level With Radio-immunoassay Result.
Development and Validation of in Vitro Cell-based Bioassays for Nuclear Receptor Activation
Effects of Andriol Testocaps in Symptomatic Late-Onset Hypogonadism (43203)